- In June 2026, Syndax Pharmaceuticals reported that its all-oral Phase 1/2 SAVE trial regimen combining Revuforj (revumenib), decitabine/cedazuridine, and venetoclax in heavily pretreated relapsed or refractory AML achieved high overall and complete remission response rates across NPM1m, KMT2Ar, and NUP98r subgroups.
- The publication of these data in the Journal of Clinical Oncology and their presentation at the EHA 2026 Congress spotlight Revuforj as the only FDA-approved menin inhibitor and underscored clinically meaningful MRD negativity rates plus substantial use as a bridge to stem cell transplant.
- We’ll now examine how the strong remission and MRD negativity data from this all-oral regimen could reshape Syndax Pharmaceuticals’ investment narrative.
Find 44 companies with promising cash flow potential yet trading below their fair value.
Syndax Pharmaceuticals Investment Narrative Recap
To own Syndax today, you need to believe Revuforj and Niktimvo can grow into durable, multi-indication franchises while the company manages high R&D spend and competition. The SAVE data strengthen Revuforj’s clinical story in genetically defined AML and may support future label or usage expansion, but they do not remove the central near term risk that any clinical, safety, or regulatory setback for these two drugs would disproportionately hit revenue and delay a path to profitability.
Among recent announcements, the US$250,000,000 offering of 2.25 percent convertible notes due 2031 stands out next to the SAVE update. For investors, that financing matters because it extends Syndax’s runway to fund Revuforj and Niktimvo trials and commercialization, potentially increasing leverage to future catalysts, while also introducing convert-related dilution risk that sits alongside the clinical and pricing uncertainties around its lead assets.
Yet against the excitement around SAVE, investors should also be aware of the less visible safety and reimbursement overhangs that could...
Read the full narrative on Syndax Pharmaceuticals (it's free!)
Syndax Pharmaceuticals' narrative projects $748.0 million revenue and $110.2 million earnings by 2029. This requires 63.1% yearly revenue growth and a $395.6 million earnings increase from -$285.4 million today.
Uncover how Syndax Pharmaceuticals' forecasts yield a $39.50 fair value, a 116% upside to its current price.
Exploring Other Perspectives
Some of the most cautious analysts expected revenue of about US$551,000,000 and only US$81,200,000 of earnings by 2029, highlighting how concerns about pricing pressure and reimbursement could look very different once the new SAVE data are fully reflected in their models.
Explore 6 other fair value estimates on Syndax Pharmaceuticals - why the stock might be worth 47% less than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Syndax Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free Syndax Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Syndax Pharmaceuticals' overall financial health at a glance.
Searching For A Fresh Perspective?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.
- This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
- Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com